Healthcare Equipment and Supplies
Company Overview of Sorin SpA
As of October 19, 2015, Sorin SpA was acquired by Cyberonics Inc. Sorin SpA, together with its subsidiaries, researches, develops, and delivers various therapeutic solutions to treat cardiovascular pathologies. It operates through Cardiac Surgery and Cardiac Rhythm Management (CRM) business units. The company provides disposable biomedical devices and systems, including heart-lung machines, oxygenators, autotransfusion systems and devices, mechanical heart valves, tissue heart valves, structureless valves, and annuloplasty rings for extracorporeal circulation during surgery. It also provides defibrillators and pacemakers, and systems for cardiac resynchronisation treatment, patient managemen...
Via Benigno Crespi, 17
Milan, MI 20159
Founded in 2004
Key Executives for Sorin SpA
Sorin SpA does not have any Key Executives recorded.
Sorin SpA Key Developments
Sorin Group Initiates TRIUMPH-CRT Clinical Trial with First Triple-Site Ventricular (Tri-V) Pacing CRT-D Device
Sep 1 15
Sorin Group announced the start of patient enrollment in its TRIUMPH-CRT clinical trial in Europe. The TRIUMPH CRT study, which will be conducted using Sorin Group’s Paradym CRT-D Tri-V device, is designed to investigate the benefits of individually optimized Tri-V pacing over standard biventricular pacing in patients with a non-Left Bundle Branch Block (LBBB) morphology. While standard CRT-D devices deliver ventricular pacing at two different ventricular sites, Paradym CRT-D Tri-V paces the ventricles at three different locations. The first patients enrolled in the study were successfully implanted at Hôpital Paris Saint-Joseph, Paris, in the electrophysiology department of Dr. Serge Cazeau, M.D., cardiologist, and at Hospital Universitario y Politécnico La Fe, Valencia, Spain by Dr. Oscar Cano, M.D., electrophysiologist. Non-LBBB patients represent more than one third of CRT implants1 yet the evidence of a benefit for these patients is weak. The current European Guidelines consider non-LBBB as a Class II indication for which the decision to implant a CRT should be individualized based on other clinical criteria.2 Poor response to Cardiac Resynchronization Therapy (CRT) in non-LBBB patients is suspected to be due to complex forms of electrical and mechanical dyssynchronies. Acute studies have suggested that non-LBBB patients may respond better to CRT if they are treated with Tri-V pacing rather than standard biventricular pacing. TRIUMPH-CRT is a multicenter, international, prospective, randomized trial which will enroll 216 patients in Europe. The objective of the primary endpoint is to demonstrate that individually optimized triple-site pacing (Tri-V pacing) is superior to standard biventricular pacing in reverse ventricular remodeling.
Sorin Group Announces European Launch of REPLY CRT-P
Jul 31 15
Sorin Group announced the launch of REPLY CRT-P, its new cardiac resynchronization therapy pacemaker. The REPLY CRT-P with its 11.3 cc in volume is the smallest cardiac resynchronization pacemaker in the world. It features proprietary algorithms aimed at better supporting heart failure management and ultimately improving patient outcome. The Sleep Apnea Monitoring (SAM) algorithm detects severe sleep apnea using a highly reliable sensor that measures ventilation. The index reported by the device has been validated against polysomnography, the gold standard method used to diagnose sleep apnea, yielding a high specificity of 85% and a sensitivity of 89%. Data from HF population studies suggest that both obstructive sleep apnea as well as central sleep apnea may be present in 30% to 50% of HF patients. If left untreated, sleep apnea increases the risk of death and HF hospitalization. SAM can screen these patients for severe sleep apnea so that they can be treated. In addition, it can be used to monitor the long term progression of the disease.
Sorin SpA Reports Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Jul 30 15
Sorin SpA reported consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, revenues were €215.6 million, up 5.2% at comparable foreign exchange and 13.1% as reported compared to the second quarter of 2014. Adjusted net profit was €16.5 million, up 47.0% compared to €11.2 million in the second quarter of 2014, including a €1.6 million impact from New Ventures and a €1.8 million unfavorable foreign exchange effect. EBITDA was €32.7 million (15.1% of revenues), up 14.3% compared to €28.6 million (15.0% of revenues) in the second quarter of 2014. EBIT was €1.1 million compared to €15.8 million in the second quarter of 2014. EBIT before special items was €18.6 million, up 10.3% compared to €16.9 million in the second quarter of 2014. In the second quarter of 2015, the Company’s free cash flow was €17.8 million.
For the six months, revenues were €405.0 million, up 3.0% at comparable foreign exchange and 10.4% as reported compared to the first half of 2014. Adjusted net profit was €24.2 million, up 8.1% compared to €22.4 million in the first half of 2014, including a €3.4 million impact from New Ventures and a €5.2 million unfavorable foreign exchange effect. EBITDA was €57.3 million (14.2% of revenues) up 3.5% compared to €55.4 million (15.1% of revenues) in the first half of 2014. EBIT was €3.0 million compared to €30.1 million in first half of 2014. EBIT before special items was €30.5 million compared to €32.4 million in the first half of 2014. Net profit was €0.6 million compared to €19.9 million in the first half of 2014. Net financial debt as of June 30, 2015 totaled €153.4 million. In the first half of 2015 the Company’s free cash flow was €2.0 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
February 26, 2015